Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) management will conduct a conference call for 11th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.cyclacel.com
Earnings Expectation
Cyclacel Pharmaceuticals, Inc. is expected to report third quarter earnings results, after market close, on Wednesday 11th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.55 per share. Looking ahead, the full year loss are expected at $ 2.68 per share.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companys oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia.
